SANA BIOTECHNOLOGY INC (SANA)
Health Care · Biotechnology · NASDAQ
Sana Biotechnology is a biotechnology company leveraging gene editing and cell engineering technologies to develop a pipeline of transformative, engineered cell-based therapies.
What SANA BIOTECHNOLOGY INC does
Sana Biotechnology is a preclinical and clinical-stage biotechnology company focused on developing engineered cell therapies to treat various diseases. The company utilizes proprietary gene-editing, cell engineering, and stem cell technologies to create cell-based product candidates. Its research and development efforts are concentrated on transformative therapies for patients with serious medical conditions.
Themes: cell therapy, gene editing, biotechnology R&D
Fundamentals
- Price$2.35 as of 2026-10-21 close
- Market cap$703M as of 2026-08-03 (share count; price 2026-10-21)
- 1-year return-58.8% 2025-10-21 close $5.71 → 2026-10-21 close $2.35
- P/En/a negative earnings
- ROE-151.8% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.97 as of 2026-09-02
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How SANA compares in its sector
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$65M | -$64M | -$0.22 | -$33M† | $2M† |
| Q1 FY2026 2026-03-31 | -$49M | -$47M | -$0.17 | -$37M | $288000 |
| Q4 FY2025 2025-12-31 | -$61M† | -$59M† | -$0.21† | -$33M† | $873000† |
| Q3 FY2025 2025-09-30 | -$44M | -$42M | -$0.16 | -$29M† | $41000† |
| Q2 FY2025 2025-06-30 | -$95M | -$94M | -$0.39 | -$33M† | -$112000† |
| Q1 FY2025 2025-03-31 | -$51M | -$49M | -$0.21 | -$49M | $136000 |
| Q4 FY2024 2024-12-31 | -$51M† | -$49M† | -$0.21† | -$47M† | $436000† |
| Q3 FY2024 2024-09-30 | -$62M | -$60M | -$0.25 | -$52M† | $4M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$57M
- Short-term investments$103M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How SANA BIOTECHNOLOGY INC looks technically
SANA BIOTECHNOLOGY INC (SANA) is trading 32.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 140 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 4 trading days ago. It is 64.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 32.8% below its 200-day average, the long-term trend line — a long-term downtrend | -32.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.22 | $3.22 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.49 | $3.49 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 3.3599. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 140 trading days ago — a "death cross", a bearish long-term signal | 140 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control | 32.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30) | 32.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($2.23 to $3.00) — its "stochastic" reading is 16 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 16.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 36 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.55 | $6.55 |
|---|---|---|
| From the 52-week high | it is 64.1% below its 52-week high (its highest price of the past year) | -64.1% |
| Above the 52-week low | it is 5.6% above its 52-week low (its lowest price of the past year) | +5.6% |
| Below the 52-week high | it is 64.1% below its highest point of the past year | 64.1% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day low about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $38.74 (set on 2021-02-22) | $38.74 |
| Given back of the 52-week move | over the past year its closes ranged ($2.27 to $5.92), and it has recovered only a small part of its fall from last year’s high — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.53 to $4.64. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 2.2% |
| From the all-time high | it is 93.9% below its all-time high | -93.9% |
| Nearest price level | it is trading 1.9% above a support level at $2.31 — a price it turned at twice since 2024-11-19, most recently on 2025-03-04. Since 2024-10-21 it has 1 such level below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.9% |
| All-time low | its lowest closing price on record is $1.26 (set on 2025-04-04) | $1.26 |
| Above the all-time low | it is 86.5% above its all-time low | +86.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 73% of it) | 73rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1779 between its high and its low — about 7.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1779 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.18 and $3.17 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.18 – $2.67 – $3.17 |
| Typical daily range (% of price) | its price moves about 7.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.6% |
| Stretch from the 200-day average | it is trading 6.4 daily ranges below its 200-day average price (32.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.60× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Gap filled | a 2.2% gap up opened on 2026-10-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 24.1 percentage points (the stock lost 24.2% while the market lost 0.1%) | -24.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 28.9 percentage points (the stock lost 25.6% while the market gained 3.3%) | -28.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 46.3 percentage points (the stock lost 36.5% while the market gained 9.8%) | -46.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 74.0 percentage points (the stock lost 58.8% while the market gained 15.2%) | -74.0% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 34% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 1.4% of the share price, which is taken to mean a barrier that gives way easily. | -34.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 31% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.40 — a volume-weighted average of daily closes over 197 sessions, not a true tick-by-tick VWAP. | -31.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 26% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.17 — a volume-weighted average of daily closes over 52 sessions, not a true tick-by-tick VWAP. | -25.8% |
Price levels it has turned at before
SANA last closed at $2.35 on 2026-10-21. Since 2024-10-21 it has turned at 1 price below its last close and 9 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.31 | Support | 1.9% below the last close | turned there twice · 2024-11-19 to 2025-03-04 |
| $2.86 | Resistance | 21.6% above the last close | turned there twice · 2025-01-22 to 2026-09-16 |
| $2.92 | Resistance | 24.3% above the last close | turned there twice · 2025-09-22 to 2026-05-19 |
| $3.02 | Resistance | 28.5% above the last close | turned there four times · 2025-03-17 to 2026-07-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $3.36.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $1.18 and $2.01 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $3.36.
This reading has stood for 17 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · lagging the market · Most volatile (6%+ typical daily range) · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$8.43 range $6.00 – $12.00; median $7.00
Analyst estimates, as of 2026-10-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SANA
- Consensus EPS estimate-$0.1335 next reporting period, as of 2026-10-19
- Estimate change, 30 days$0.00 from -$0.1335, on 2026-09-14, 35-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant capital requirements and need for future financing to sustain operations.","Substantial clinical, regulatory, and technical risks involved in the development of engineered cell therapies.","Risks related to intellectual property protection and the evolving regulatory landscape for biotechnology."]
What changed in the latest 10-Q
AI-assisted comparison of SANA's 10-Q filed 2026-05-11 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 2025 Annual Report filed March 3, 2026 (older filing references 2024 Annual Report filed March 17, 2025)
- Newer filing states therapeutic areas include 'oncology' alongside type 1 diabetes and B-cell mediated autoimmune diseases
- Newer filing introduces SG227 as a CD8-targeted fusosome for BCMA-directed CAR T cells in multiple myeloma, with clinical testing expected mid-2027
- Newer filing states SC451 IND filing and Phase 1 trial expected 'as early as this year' (2026)
- Newer filing states SG293 initial clinical data expected 'as early as this year' (2026)
- Newer filing reports positive 14-month results from UP421 IST announced in March 2026, including no drug product-related adverse events and graft survival through 14 months
- Newer filing confirms 14-month C-peptide production and appropriate islet cell function demonstrated by mixed meal tolerance test
- Newer filing states suspension of SC291 and SC262 development is already in effect and winding down of GLEAM and VIVID trials is ongoing
- Removed:
- Older filing reference to 'repair and control genes' changed to 'repair or control genes' in newer
- Older filing's statement that company is 'preclinically developing SC451' removed; newer filing treats SC451 as an advanced program
- Older filing's reference to UP421 as 'Phase 1 investigator-sponsored first-in-human study' removed; newer simply calls it IST
- Older filing's statement about expecting to file IND and begin Phase 1 for SC451 'as early as 2026' removed (now expected 'as early as this year' in 2026 filing)
- Older filing's six-month UP421 results details (C-peptide presence, mixed meal tolerance test responses, 12-week PET-MRI scanning, 85th ADA Scientific Sessions presentation) partially replaced with 14-month results in newer
- Older filing's reference to SG299 product candidate and comparison data removed; newer filing only references SG293
- Older filing's statement that SG293 IND filing expected 'as early as 2027' removed; newer filing expects clinical data 'as early as this year'
- Older filing's statement about 'beginning to wind down' GLEAM and VIVID trials removed; newer states winding down is occurring
- Reworded:
- Older: 'developing ex vivo and in vivo cell engineering platforms to revolutionize treatment of various diseases' changed to Newer: 'platforms to revolutionize treatment across a broad array of therapeutic areas'
- Older: 'cell-specific delivery of genetic payloads that integrate into the genome' changed to Newer: 'cell-specific delivery of genetic payloads, known as chimeric antigen receptors (CARs)'
- Older: 'allows for cell-specific, in vivo delivery' changed to Newer: 'enables cell-specific, in vivo delivery'
- Older: 'intend to explore SG293 in both B-cell cancers' changed to Newer: 'plan to develop SG293 in a range of B cell cancers'
- Older: 'avoiding potentially troublesome delivery' changed to Newer: 'avoiding potentially problematic delivery'
- Older: 'plan to prioritize further development' and 'have suspended development' changed to Newer: 'prioritization of further development' and 'suspended development' (different verb tenses and structures)
- Notes:
- Newer filing text appears truncated at end ('In August 2025, The New England Journal of Medicine published a journal article titled "Survival of Transplanted Allogeneic Beta Cells'); comparison limited to available text
- Older filing text also appears truncated ('We continue preclinical development of SC451, and recent regulatory interactions, includin'); full sentence unavailable for comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for SANA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SANA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 67,222,678
- Reported value $234,607,146
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about SANA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
SANA had 38,725,699 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
SANA had 12.9% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.96 days to cover at the same settlement.
- Reported short interest (shares) 38,725,699
- Short interest (% of shares outstanding) 12.9%
- Prior settlement (shares) 41,374,811
- Reported change -6.4%
- Days to cover (reported) 8.96
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
SANA BIOTECHNOLOGY INC is found in…
Frequently asked questions
What does SANA BIOTECHNOLOGY INC (SANA) do?
Sana Biotechnology is a preclinical and clinical-stage biotechnology company focused on developing engineered cell therapies to treat various diseases. The company utilizes proprietary gene-editing, cell engineering, and stem cell technologies to create cell-based product candidates. Its research and development efforts are concentrated on transformative therapies for patients with serious medical conditions.
What sector is SANA BIOTECHNOLOGY INC (SANA) in?
SANA BIOTECHNOLOGY INC (SANA) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Is SANA BIOTECHNOLOGY INC (SANA) overbought or oversold right now?
SANA BIOTECHNOLOGY INC (SANA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 32, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SANA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.